Error al deserializar el cuerpo del mensaje de respuesta para la operación 'Translate'. Se superó la cuota de longitud del contenido de cadena (8192) al leer los datos XML. Esta cuota se puede aumentar cambiando la propiedad MaxStringContentLength en el objeto XmlDictionaryReaderQuotas que se usa para crear el lector XML. Línea 1, posición 9867.
NEW YORK, May 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Specialty Pharmaceutical Industry - 2011 Yearbook
http://www.reportlinker.com/p0512130/Specialty-Pharmaceutical-Industry---2011-Yearbook.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Specialty Pharmaceutical Industry - 2011 Yearbook
Summary
GBI Research's "Specialty Pharmaceutical Industry - 2011 Yearbook" essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.
Scope
The report covers -
- Annualized market data for the specialty pharmaceutical market from 2001 to 2009, with forecasts to 2017.
- Market analysis for the eight major indications in the global specialty pharmaceutical market which includes HIV/AIDS, age related macular degenerative disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma.
- Data and analysis on the specialty pharmaceutical market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key M&A activities and licensing agreements that took place from 2004 to 2010 in the specialty pharmaceutical market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 9
2 Specialty Pharmaceutical Market- 2011 Yearbook: Introduction 12
2.1 Scope 12
2.2 GBI Research Report Guidance 12
3 Specialty Pharmaceutical Market- 2011 Yearbook: HIV Therapeutics Market 13
3.1 Disease Overview 13
3.2 Market Overview 14
3.3 Global HIV Therapeutics Market: Market Characterization 14
3.3.1 Market Forecasts 14
3.3.2 Annual Cost of Therapy 16
3.3.3 Usage Patterns 18
3.3.4 Geographical Distribution 24
3.4 HIV Therapeutics Market: Drivers and Restraints 26
3.4.1 Market Drivers 26
3.4.2 Market Restraints 29
4 Specialty Pharmaceutical Market- 2011 Year Book: Age Related Macular Degenerative Disorder 31
4.1 Disease Overview 31
4.2 Market Overview 31
4.3 Age Related Macular Degenerative Disorder: Market Characterization 32
4.3.1 Market Forecasts 32
4.3.2 Geographical Distribution 33
4.3.3 Annual Cost of Therapy 34
4.3.4 Usage Patterns 35
4.4 Age Related Macular Degenerative Disorder: Drivers and Restraints 39
4.4.1 Market Drivers 39
4.4.2 Market Restraints 40
5 Specialty Pharmaceutical Market- 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD) 41
5.1 Introduction 41
5.2 Attention Deficit Hyperactive Disorder: Market Characterization 41
5.2.1 Market Forecasts 41
5.2.2 Geographical Distribution 43
5.2.3 Annual Cost of Therapy 44
5.2.4 Usage Patterns 45
5.3 Attention Deficit Hyperactive Disorder Market: Drivers and Restraints 50
5.3.1 Market Drivers 50
5.3.2 Market Restraints 50
6 Specialty Pharmaceutical Market- 2011 Yearbook: Alzheimer's Disease 51
6.1 Introduction 51
6.2 Alzheimer's disease: Market Characterization 51
6.2.1 Market Forecasts 51
6.2.2 Geographical Distribution 53
6.2.3 Annual Cost of Therapy 54
6.2.4 Usage Patterns 55
6.3 Alzheimer's Disease Market: Drivers and Restraints 60
6.4 Market Drivers 60
6.5 Market Restraints 60
7 Specialty Pharmaceutical Market- 2011 Yearbook: Colorectal Cancer 61
7.1 Introduction 61
7.2 Colorectal Cancer: Market Characterization 61
7.2.1 Market Forecasts 61
7.2.2 Geographical Distribution 63
7.2.3 Annual Cost of Therapy 64
7.2.4 Usage Patterns 65
7.3 Colorectal Cancer Market: Drivers and Restraints 70
7.3.1 Market Drivers 70
7.3.2 Market Restraints 70
8 Specialty Pharmaceutical Market- 2011 Yearbook: Rheumatoid Arthritis 71
8.1 Introduction 71
8.2 Rheumatoid Arthritis: Market Characterization 71
8.2.1 Market Forecasts 71
8.2.2 Annual Cost of Therapy 73
8.2.3 Treatment Usage Patterns 74
8.2.4 Geographical Distribution 79
8.3 Rheumatoid Arthritis Market: Drivers and Restraints 80
8.3.1 Market Drivers 80
8.3.2 Market Restraints 80
9 Specialty Pharmaceutical Market- 2011 Yearbook: Epilepsy 81
9.1 Introduction 81
9.2 Epilepsy: Market Characterization 81
9.2.1 Market Forecasts 81
9.2.2 Geographical Distribution 83
9.2.3 Annual Cost of Therapy 84
9.2.4 Usage Patterns 85
9.3 Epilepsy Market: Drivers and Restraints 90
9.3.1 Market Drivers 90
9.3.2 Market Restraints 90
10 Specialty Pharmaceutical Market- 2011 Yearbook: Glaucoma 91
10.1 Introduction 91
10.2 Glaucoma: Market Characterization 91
10.2.1 Market Forecasts 91
10.2.2 Geographical Distribution 93
10.2.3 Annual Cost of Therapy 94
10.2.4 Usage Patterns 95
10.3 Glaucoma Market: Drivers and Restraints 100
10.3.1 Drivers of the Glaucoma Market 100
10.3.2 Barriers for the Glaucoma Market 100
11 Specialty Pharmaceutical Market- 2011Yearbook: Pipeline Analysis 102
11.1 Specialty Pharmaceutical Pipeline: HIV market 105
11.2 Molecule Profile for Promising Drugs under Clinical Development: HIV 106
11.2.1 Rilpivirine hydrochloride (TMC278) 106
11.2.2 Elvitegravir 107
11.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) 108
11.2.4 Racivir 109
11.2.5 Apricitabine (ATC) 110
11.2.6 Tesamorelin 111
11.3 Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration 112
11.4 Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration 113
11.4.1 VEGF Trap-Eye 113
11.5 Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder 114
11.6 Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder 115
11.6.1 ABT-894 (Sofinicline) 115
11.6.2 Eltoprazine 115
11.6.3 AZD3480 (TC-1734) (Isopronicline) 116
11.7 Specialty Pharmaceutical Pipeline: Alzheimer's Disease 117
11.8 Molecular Profile for the Promising Drugs under Clinical Development: Alzheimer's Disease 118
11.8.1 Bapineuzumab 118
11.8.2 Gammagard 119
11.8.3 Dimebon 120
11.8.4 Rember (Trx0014) (methylthionium chloride) 120
11.9 Specialty Pharmaceutical Pipeline: Colorectal Cancer 122
11.10 Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer 123
11.10.1 Aflibercept 123
11.10.2 Brivanib 124
11.10.3 OncoVAX 125
11.10.4 TroVax 127
11.10.5 KRX-0401 (Perifosine) 128
11.11 Specialty Pharmaceutical Pipeline: Rheumatoid Arthritis 129
No hay comentarios:
Publicar un comentario